Abstract 340P
Background
The optimal follow-up strategy for the detection of relapse in patients with diffuse large B-cell lymphoma (DLBCL) has not been clarified. In this report, we assess the role of laboratory tests and CT for surveillance and investigate the risk factors for recurrence.
Methods
We reviewed the clinical records of patients who achieved CR by PET-CT after received R-CHOP like regimen in our hospital for DLBCL between February 2008 and February 2022. Clinical evaluation post treatment was done every 3-6 months in the first 2 years, and every 6–12 years in the 3 coming years.
Results
A total of 324 patients were eligible for inclusion in this study. The median duration of follow-up for surviving patients was 4.3 years. The cumulative incidence of relapse without death at 2 and 5 years was 13.3% and 21.6%. Overall, 1453 CT scans were carried out through surveillance. The total of 64 patients relapsed within the observation period. Of these, 19 patients were detected to have recurrence on surveillance CT scans. On univariate analysis, ABC-type, extranodal (EN) stites > 1 at diagnosi, and relative dose intensity (RDI) < 90% were risk factors for recurrence. On Fine-Gray regression analysis, ABC-type (HR 2.1, 95% confidence interval [95% CI] 1.1-3.7. p=0.018) and EN sites > 1 at diagnosis (HR 1.8, 95% CI 1.1-3.6. p=0.031) were independent risk factors for recurrence. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the surveillance value of soluble interleukin-2 (sIL-2R) (HR 0.81, 95% CI 0.72–0.90) was significantly larger than lactate dehydrogenase (LDH) (0.65, 95% CI 0.55–0.75. p=0.024). While in the normal pretreatment sIL-2R group, the AUC of the ROC curve of sIL2R was small (0.57), however, in the high pretreatment sIL-2R group, the AUC of the ROC curve of sIL2-R (0.83, 95% CI 0.74-0.91) was high. We defined the best cutoff value of the sIL2-R as 607.5 using a ROC curve in the high pretreatment sIL-2R group (Sensitivity 0.63. Specificity 0.88).
Conclusions
Routine surveillance CT scans were of limited value in detecting asymptomatic relapse. ABC-type and EN sites were independent risk factors for recurrence. The measurement of sIL-2R might be useful for surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract